




The relative strengths and weaknesses of Zentalis Pharmaceuticals Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Zentalis Pharmaceuticals Inc compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 127% points. The greatest weakness of Zentalis Pharmaceuticals Inc is the variable Other Revenues, reducing the Economic Capital Ratio by 13% points.

The company's Economic Capital Ratio, given in the ranking table, is 302%, being 89% points above the market average of 213%.

Input Variable	Value in 1000 USD
Assets, Current	496,718
Cost of Goods Sold	0
Intangible Assets	3,736
Liabilities, Current	69,367
Liabilities, Non-Current	44,930
Other Assets	45,415
Other Compr. Net Income	3,661
Other Expenses	44,967
Other Liabilities	0
Other Net Income	6,603
Other Revenues	0
Property and Equipment	5,819
Research and Development	189,590
Selling, General and Administrative Expense	64,351

Output Variable	Value in 1000 USD
Assets	551,688
Liabilities	114,297
Expenses	298,908
Revenues	0
Stockholders Equity	437,391
Net Income	-292,305
Comprehensive Net Income	-290,474
BaseVar	487,578
ECR before LimitedLiability	199%
Economic Capital Ratio	302%